No Data
CICC: Upgraded Aier Ophthalmology-B(06855) target price to 55 Hong Kong dollars, maintaining 'Outperform Industry' rating.
Recently, the company announced that the company's original class 1 new drug, FAK/ALK/ROS1 triple tyrosine kinase inhibitor (TKI) APG-2449, has been approved by the National Medical Products Administration, and will conduct two Phase III clinical studies for second-generation ALK TKI resistant or intolerant non-small cell lung cancer (NSCLC) or first-line ALK-positive advanced NSCLC.
HK Stock Market News | ASB Medicine-B (06855) surged over 4% again. APG-2449 approved for Phase III clinical trial, expected to enter a new stage of listing in the US.
A-Share Medicine-B (06855) rose over 4% again, reaching a high of HK$46.45, a three-year high. As of the time of writing, it's up 4.62%, at HK$46.45, with a turnover of HK$73.8857 million.
Would Ascentage Pharma Group International (HKG:6855) Be Better Off With Less Debt?
Chinese Regulator Clears Ascentage Pharma's Cancer Drug for Phase Three Studies
Akeso Medical - B (06855): APG-2449 has obtained CDE approval to conduct Phase III clinical trials for the treatment of non-small cell lung cancer.
AstraZeneca Pharmaceutical - B (06855) announced that the company's original class 1 new drugs APG2449, FAK/ALK...
ASCENTAGE-B: INTERIM REPORT 2024
No Data
No Data
